GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Krystal Biotech Inc (NAS:KRYS) » Definitions » PB Ratio

KRYS (Krystal Biotech) PB Ratio : 5.35 (As of Dec. 13, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Krystal Biotech PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-13), Krystal Biotech's share price is $164.84. Krystal Biotech's Book Value per Share for the quarter that ended in Sep. 2024 was $30.81. Hence, Krystal Biotech's PB Ratio of today is 5.35.

The historical rank and industry rank for Krystal Biotech's PB Ratio or its related term are showing as below:

KRYS' s PB Ratio Range Over the Past 10 Years
Min: 3.68   Med: 5.81   Max: 7.31
Current: 5.35

During the past 8 years, Krystal Biotech's highest PB Ratio was 7.31. The lowest was 3.68. And the median was 5.81.

KRYS's PB Ratio is ranked worse than
78.58% of 1279 companies
in the Biotechnology industry
Industry Median: 2.48 vs KRYS: 5.35

During the past 12 months, Krystal Biotech's average Book Value Per Share Growth Rate was 14.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 23.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 27.10% per year.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Krystal Biotech was 45.60% per year. The lowest was 20.10% per year. And the median was 33.60% per year.

Back to Basics: PB Ratio


Krystal Biotech PB Ratio Historical Data

The historical data trend for Krystal Biotech's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Krystal Biotech PB Ratio Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial 4.74 4.05 2.97 3.91 4.50

Krystal Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.33 4.50 6.35 6.28 5.91

Competitive Comparison of Krystal Biotech's PB Ratio

For the Biotechnology subindustry, Krystal Biotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Krystal Biotech's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's PB Ratio distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's PB Ratio falls into.



Krystal Biotech PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Krystal Biotech's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=164.84/30.805
=5.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Krystal Biotech  (NAS:KRYS) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Krystal Biotech PB Ratio Related Terms

Thank you for viewing the detailed overview of Krystal Biotech's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Krystal Biotech Business Description

Traded in Other Exchanges
Address
2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Executives
Krish S Krishnan director, 10 percent owner, officer: President and CEO 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Suma Krishnan director, 10 percent owner, officer: Chief Operating Officer 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Julian S Gangolli director 4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Kathryn Romano officer: Chief Accounting Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Catherine Mazzacco director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Daniel Janney director PO BOX 7414, JACKSON WY 83002
Andrew C. Orth officer: Chief Commercial Officer 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Dino A Rossi director 61 WATROO POINT, DANIEL ISLAND SC 29492
Everett Rand Sutherland director 29 HARTWELL AVENUE, LEXINGTON MA 02421
Christopher Mason director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Jing L. Marantz director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Jennifer Chien officer: Chief Commercial Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Antony A Riley officer: Chief Financial Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538
R Douglas Norby director C/O MAGNACHIP SEMICONDUCTOR, INC., 20400 STEVENS CREEK BOULEVARD, SUITE 370, CUPERTINO CA 95014
Sun Pharma (netherlands) B.v. 10 percent owner POLARISAVENUE 87, 2132 JH HOOFDDORP P7 00000